Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review

Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon <i>EGFR</i> mutations show variable responses, and resistance often develops. The C...

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	Wenting Lu, Jiayi Sun, Yawan Jing, Jing Xu, Chengming Huang, Yi Deng, Panwen Tian, Yalun Li
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Subjects:	NSCLC <i>EGFR</i> mutation <i>EGFR</i>-TKI osimertinib gefitinib bevacizumab
Online Access:	https://www.mdpi.com/1718-7729/32/4/201